MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells

Toxicology Letters

Volumn 221, Issue 1, 2013, Pages 23-30

  Liu, Yangbo ^a   He, Gang ^a   Wang, Yan ^a   Guan, Xinging ^a   Pang, Xueli ^a   Zhang, Bo ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Cell cycle; Colon cancer; MCM 2; TSA

Indexed keywords

MINICHROMOSOME MAINTENANCE PROTEIN 2; TRICHOSTATIN A;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE REGULATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG TARGETING; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE; COLON CANCER; MCM-2; TSA;

ADENOCARCINOMA; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MOLECULAR TARGETED THERAPY; NUCLEAR PROTEINS; RNA, SMALL INTERFERING; UP-REGULATION;

EID: 84879819383     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.05.643     Document Type: Article

References (30)

1. Ananthanarayanan V., Deaton R.J., Yang X.J., Pins M.R., Gann P.H. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 2006, 6:73.
2. Beumer J.H., Tawbi H. Role of histone deacetylases and their inhibitors in cancer biology and treatment. Current Clinical Pharmacology 2010, 5:196-208.
3. Bots M., Johnstone R.W. Rational combinations using HDAC inhibitors. Clinical Cancer Research 2009, 15:3970-3977.
4. Chang J., Varghese D.S., Gillam, et al. Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. British Journal of Cancer 2012, 106:116-125.
5. Forsburg S.L. Eukaryotic MCM proteins: beyond replication initiation. Microbiology and Molecular Biology Reviews 2004, 68:109-131.
6. Ghazy S.E., Helmy I.M., Baghdadi H.M. Maspin and MCM-2 immunoprofiling in salivary gland carcinomas. Diagnostic Pathology 2011, 6:89.
7. Giaginis C., Vgenopoulou S., Vielh P., Theocharis S. MCM proteins as diagnostic and prognostic tumor markers in the clinical setting. Histology and Histopathology 2010, 25:351-370.
8. 12 myocytes via ASK1-MKK3/4/6-JNK and p38 mitogen-activated protein kinase pathways. Journal of Cellular Biochemistry 2010, 111:564-573.
9. Hsu Y.F., Sheu J.R., Lin C.H., et al. Trichostatin A and sirtinol suppressed survivin expression through AMPK and p38MAPK in HT29 colon cancer cells. Biochimica et Biophysica Acta 2012, 1820:104-115.
10. Huang B., Hu B., Su M., Tian D., Guo Y., Lian S., Liu Z., Wu X., Li Q., Zheng R., Gao Y. Potential role of minichromosome maintenance protein 2 as a screening biomarker in esophageal cancer high-risk population in China. Human Pathology 2011, 42:808-816.
11. Januchowski R., Dabrowski M., Ofori H., Jagodzinski P.P. Trichostatin A down-regulate DNA methyltransferase 1 in Jurkat T cells. Cancer Letters 2007, 246:313-317.
12. Jin H., Park J.Y., Choi H.J., Choung P.H. HDAC Inhibitor Trichostatin A promotes proliferation and odontoblast differentiation of human dental pulp stem cells. Tissue Engineering Part A 2013, 19:613-624.
13. Kelly A.E., Ghenoiu C., Xue J.Z., et al. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science 2010, 330:235-239.
14. Kodani I., Shomori K., Osaki M., Kuratate I., Ryoke K., Ito H. Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normal-dysplasia-carcinoma sequence of the oral mucosa. Pathobiology 2001, 69:150-158.
15. Konsoula Z., Velena A., Lee R., Dritschilo A., Jung M. Histone deacetylase inhibitor: antineoplastic agent and radiation modulator. Advances in Experimental Medicine and Biology 2011, 720:171-179.
16. Lei M. The MCM complex: its role in DNA replication and implications for cancer therapy. Current Cancer Drug Targets 2005, 5:365-380.
17. Marks P.A., Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. Journal of Cellular Biochemistry 2009, 107:600-608.
18. Noro R., Miyanaga A., Minegishi Y., et al. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. Cancer Science 2010, 101:1424-1430.
19. Osaki M., Osaki M., Yamashita H., Shomori K., Yoshida H., Ito H. Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: correlations with Ki-67 and P53 expression, and apoptosis. International Journal of Molecular Medicine 2002, 10:161-168.
20. Saydam O., Senol O., Schaaij-Visser T.B., Pham T.V., Piersma S.R., Stemmer-Rachamimov A.O., Wurdinger T., Peerdeman S.M., Jimenez C.R. Comparative protein profiling reveals minichromosome maintenance (MCM) proteins as novel potential tumor markers for meningiomas. Journal of Proteome Research 2010, 9:485-494.
21. Son D.S., Wilson A.J., Parl A.K., Khabele D. The effects of the histone deacetylase inhibitor romidepsin (FK228) are enhanced by aspirin (ASA) in COX-1 positive ovarian cancer cells through augmentation of p21. Cancer Biology and Therapy 2010, 9:928-935.
22. Suzuki S., Kurata M., Abe S., Miyazawa R., Murayama T., Hidaka M., Yamamoto K., Kitagawa M. Overexpression of MCM2 in myelodysplastic syndromes: association with bone marrow cell apoptosis and peripheral cytopenia. Experimental and Molecular Pathology 2012, 92:160-166.
23. Torres-Rendon A., Roy S., Craig G.T., Speight P.M. Expression of Mcm2, geminin and Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding squamous-cell carcinomas. British Journal of Cancer 2009, 100:1128-1134.
24. Wilson A.J., Byun D.S., Popova N., et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Journal of Biological Chemistry 2006, 281:13548-13558.
25. Wojnar A., Kobierzycki C., Krolicka A., Pula B., Podhorska-Okolow M., Dziegiel P. Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers. Folia Histochemica et Cytobiologica 2010, 48:442-446.
26. Wolpin B.M., Mayer R.J. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-1310.
27. Yan G., Graham K., Lanza-Jacoby S. Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. Molecular Carcinogenesis 2012, doi: 10.1002/mc.21875.
28. Yang C., Wen Y., Li H., Zhang D., Zhang N., Shi X., Jiang B., Ma X., Yang P., Tang H., Peng Z., Yang Y. Overexpression of minichromosome maintenance 2 predicts poor prognosis in patients with gastric cancer. Oncology Reports 2012, 27:135-142.
29. Zhang Z., Yamashita H., Toyama T., et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Research and Treatment 2005, 94:11-16.
30. Zhu P., Martin E., Mengwasser J., Schlag P., Janssen K.P., Göttlicher M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5:455-463.